IDH1 and central nervous system cancer: While many studies of glioma have historically combined IDH1/2 mutant and wild-type cohorts when analyzing treatment outcomes in glioma patients, recently, more concerted efforts have been made to analyze the outcomes of IDH1/2 mutant gliomas as a distinct entity [18,19,20].